CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a combination of monoclonal antibodies — compared with induction with either agent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback